Navigation Links
Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
Date:7/7/2008

re treated with the Genous stent. Antiplatelet therapy was stopped five days prior to scheduled surgery in all patients, with an average antiplatelet therapy duration of 12.5 days. After NCS, thienopyridine administration was not restarted and 100 mg per day of ASA was the only cardiac antiplatelet therapy at discharge. MACE, including in-hospital cardiac death, MI, stent thrombosis, surgical bleeding complications, need for revascularization and 30 day after surgery clinical follow- up, were evaluated.

The results of the study indicated an optimal acute procedural result in all patients. The 22 patients included in the study underwent uneventful NCS 10 to 22 days after coronary stent deployment. MACE rates were 0% at in-hospital follow-up and at one month follow-up.

"The Genous stent may offer a new, important and feasible therapeutic strategy for patients needing to undergo life-saving or undeferrable major noncardiac surgery early after coronary stent deployment," said Piscione.

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's EPCs to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous(TM) Bio-engineered R stent(TM), an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Scoreflex(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

<
'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015  Astellas today announced topline results from ... and safety of intravenous (IV) and oral isavuconazole, ... for adults with candidemia and other invasive ... that the trial did not meet its primary ... isavuconazole-treated patients at the end of IV therapy ...
(Date:7/29/2015)... -- Nektar Therapeutics (Nasdaq: NKTR ) will announce its financial ... Wednesday, August 5, 2015, after the close of U.S.-based financial ... will host a conference call to review the results beginning ... The press release and a live audio-only ... link that is posted on the home page and Investor ...
(Date:7/29/2015)... July 29, 2015 Unilife Corporation (NASDAQ: ... manufacturer and supplier of injectable drug delivery systems, ... of instant patch pumps for insulin. ... insulin pump that does not require filling or ... and pre-assembled like an insulin pen, only three ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Unilife Introduces World's First Instant Patch Pump for Insulin 2Unilife Introduces World's First Instant Patch Pump for Insulin 3Unilife Introduces World's First Instant Patch Pump for Insulin 4
... March 16 ViroPharma Incorporated (Nasdaq: VPHM ) announced today that the company will provide a live audio webcast of its investor day event, focusing on Cinryze ... ... ... ...
... and ATLANTA , March 15 ... announced results from an analysis of one-year subset data ... diabetes on clinical and angiographic outcomes in heart attack ... Stent System or the Express® bare-metal stent.  The results ...
Cached Medicine Technology:ViroPharma To Host Investor Day 2ViroPharma To Host Investor Day 3ViroPharma To Host Investor Day 4ViroPharma To Host Investor Day 5Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 2Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 3Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 4Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 5Study Shows Superior Efficacy for TAXUS(R) Express(R) Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack 6
(Date:7/30/2015)... ... 30, 2015 , ... Between 2012 and 2014 HIV infection rates rose from ... on June 17th. Those untreated heroin use disorders share their needles and spread the ... needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent ...
(Date:7/30/2015)... ... 30, 2015 , ... Ocean Hills Recovery has officially been accredited by CARF ... No recommendations means CARF found no areas in the OHR program that needed improvement, ... of all facilities receive. In addition, Ocean Hills was granted the maximum certification period ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription ... Saturday, September 26, 2015 from 10:00 AM to 2:00 PM local time. On ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Tisch Cancer ... Designation , The Tisch Cancer Institute (TCI) at the Icahn School of Medicine ... TCI joins an elite group of 69 cancer institutions nationwide that have earned ...
(Date:7/30/2015)... , ... July 30, 2015 , ... InventHelp, ... Texas, has designed a personal-care device that makes it easy to apply lotion or ... eliminate the need for assistance when applying lotion or medication to the back, and ...
Breaking Medicine News(10 mins):Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... been characterized as the most materialistic generation in history: ... owning luxury handbags and the latest technology devices. ... of teen materialism. In fact, research suggests that parents ... therefore, highly materialistic parents and peers are likely to ...
... ... headquartered in Nashville must pay $19.4 million plus interest to the United States government after ... , ... 2010 -- United States District Court Judge William J. Haynes, Jr. issued an order on ...
... ... Center School of Medicine has designed a first-of-its-kind program to alleviate ... Track (FMAT), has been approved by the Liaison Committee for Medical ... will complete their training one year earlier than students in the ...
... ... a new effort by Congress to reduce pharmacy choices, arbitrarily set prices, ... program. FEHBP enrollees feel that OPM does a great job managing ... the program by forcing OPM to change FEHBP’s pharmacy benefits. This was ...
... for some patients with operable disease, review finds , ... for patients with operable non-small cell lung cancer, say ... meta-analysis of 34 studies involving almost 8,500 patients (and ... years was 64 percent for patients who had chemotherapy ...
... Tuesday, President Obama signed into law U.S. health care ... affect them, their families, and businesses. The ... 2006 legislation in Massachusetts requiring all adults in the ... mandate. A new article from The Milbank Quarterly ...
Cached Medicine News:Health News:Counteracting teens' logo lust 2Health News:Fresenius Medical Holdings, Inc. Ordered To Pay $19.4 Million For Fraudulent Medicare Claims 2Health News:Fresenius Medical Holdings, Inc. Ordered To Pay $19.4 Million For Fraudulent Medicare Claims 3Health News:Primary Care Physician Shortage: Texas Tech University Health Sciences Center Has the Solution 2Health News:Primary Care Physician Shortage: Texas Tech University Health Sciences Center Has the Solution 3Health News:Primary Care Physician Shortage: Texas Tech University Health Sciences Center Has the Solution 4Health News:PCMA: Federal Enrollees Don't Want Congress to Reduce Pharmacy Choices, Impose Price Controls in FEHBP 2Health News:Chemo May Boost Survival After Lung Cancer Surgery 2Health News:Massachusetts health care reform reviewed as a model for national plan 2
... Lensmeter is designed for fast and easy ... Auto mode, the readings are automatically held ... lenses are automatically detected. The sophisticated alignment ... lens. The TL-2000A has been designed with ...
The Kowa Pro-lll is Kowas' flagship camera....
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
FF 450plus IRu Fundus camera with Visupac / System 431. Digital results in all capture modes and unlimited Visupac software....
Medicine Products: